Associations between SDF-1/CXCR4 polymorphisms or SDF-1/CXCR4 abundance in tumor specimens and clinical outcome in several but not all studies might suggest a role of SDF-1/CXCR4 signaling in metastatic progression in a variety of tumor entities, such as renal cell carcinoma (97), prostate cancer (98), HNSCC (99–102), esophagogastric cancer (103), colorectal cancer (74), hepatocellular carcinoma (104), or osteosarcoma (105). This evidence concerns the gene CXCL12 and neoplasm.